| Tushar R Gaonkar, MD | |
|
4205 Westbrook Dr, Aurora, IL 60504-4124 | |
| (630) 527-1818 | |
| (630) 527-1244 |
| Full Name | Tushar R Gaonkar |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 30 Years |
| Location | 4205 Westbrook Dr, Aurora, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083604185 | NPI | - | NPPES |
| 036093750 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 036-093750 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Residential Home Health | Downers grove, IL | Home health agency |
| Edward Hospital | Naperville, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dupage Medical Group Ltd | 5496667941 | 1209 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.
People with even minimally symptomatic obstructive sleep apnea (OSA) may be at increased risk for cardiovascular disease because of impaired endothelial function and increased arterial stiffness, according to a study from the Oxford Centre for Respiratory Medicine in the UK.
Obese teenagers already show signs of hormonal differences from normal-weight peers that may make them prone to weight gain, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Barr Pharmaceuticals has announced that Gedeon Richter, Plc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Novartis Pharmaceutical Corporation's LAMISIL (terbinafine hydrochloride) Tablets, 250 mg. The approval follows the expiration of pediatric exclusivity for LAMISIL.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.
› Verified 9 days ago
| Entity Name | Dupage Medical Group Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801833983 PECOS PAC ID: 5496667941 Enrollment ID: O20031110000535 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.
People with even minimally symptomatic obstructive sleep apnea (OSA) may be at increased risk for cardiovascular disease because of impaired endothelial function and increased arterial stiffness, according to a study from the Oxford Centre for Respiratory Medicine in the UK.
Obese teenagers already show signs of hormonal differences from normal-weight peers that may make them prone to weight gain, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Barr Pharmaceuticals has announced that Gedeon Richter, Plc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Novartis Pharmaceutical Corporation's LAMISIL (terbinafine hydrochloride) Tablets, 250 mg. The approval follows the expiration of pediatric exclusivity for LAMISIL.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tushar R Gaonkar, MD Po Box 713260, Chicago, IL 60677-1260 Ph: (630) 469-9200 | Tushar R Gaonkar, MD 4205 Westbrook Dr, Aurora, IL 60504-4124 Ph: (630) 527-1818 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.
People with even minimally symptomatic obstructive sleep apnea (OSA) may be at increased risk for cardiovascular disease because of impaired endothelial function and increased arterial stiffness, according to a study from the Oxford Centre for Respiratory Medicine in the UK.
Obese teenagers already show signs of hormonal differences from normal-weight peers that may make them prone to weight gain, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Barr Pharmaceuticals has announced that Gedeon Richter, Plc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Novartis Pharmaceutical Corporation's LAMISIL (terbinafine hydrochloride) Tablets, 250 mg. The approval follows the expiration of pediatric exclusivity for LAMISIL.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.
› Verified 9 days ago
Joseph Robert Rojas, Family Medicine Medicare: Medicare Enrolled Practice Location: 2020 Ogden Ave, Aurora, IL 60504 Phone: 630-978-4850 Fax: 630-978-6865 | |
Jurate Kunickaite, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2285 Sequoia Dr, Aurora, IL 60506 Phone: 630-859-6859 | |
Daniel E Hrad, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4205 Westbrook Dr, Aurora, IL 60504 Phone: 630-527-1818 Fax: 630-527-1244 | |
Aruna Galla-pagadala, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2285 Sequoia Dr, Aurora, IL 60506 Phone: 630-859-6700 | |
Kuchipudi Veerraju, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 475 N Farnsworth Ave, Aurora Medical Clinic, Aurora, IL 60505 Phone: 630-898-0022 Fax: 630-898-2933 | |
Dr. Robert D. Paras, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2111 Ogden Ave, Aurora, IL 60504 Phone: 630-978-3800 Fax: 630-862-3085 | |
Dr. Mona Habiba Waheed, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2285 Sequoia Dr, Aurora, IL 60506 Phone: 630-859-6700 |